Rising Adoption of Bone Marrow Transplant is Pushing Growth of the Global Sickle Cell Disease Treatment Market
The global sickle cell disease treatment market is driven by rising adoption of bone marrow transplant. Sickle cell disease is a group of inherited red blood cell disorders. The disease results from a genetic mutation that causes an abnormal type of hemoglobin called hemoglobin S to form in red blood cells.
Sickle Cell Disease Treatment Market Demand causes red blood cells to become rigid and form into a C-like shape. These oddly shaped blood cells can get stuck in small blood vessels, which can slow or block blood flow and oxygen to parts of the body. This is what causes painful sickle cell crises. Treatment options for sickle cell disease depend on how severe the symptoms are and include medications to treat pain and other symptoms, blood transfusions, antibiotics to prevent infections, surgeries for complications like strokes, and bone marrow transplants or gene therapy for severe cases.
The Global sickle cell disease treatment market is estimated to be valued at US$ 3.20 Bn in 2025 and is expected to exhibit a CAGR of 15% over the forecast period 2025 to 2031.
Key Takeaways
Key players operating in the sickle cell disease treatment are Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc. Key players are focusing on developing new drugs and treating patients with the disease. Novartis AG’s hydroxyurea is one of the standard treatments for sickle cell disease.Growing demand for pain management drugs and supportive care is driving market growth. Pain crises are common in sickle cell disease patients and demand for pain management drugs is increasing. Supportive care like folic acid supplements and vaccinations are also seeing higher demand.
Get More Insights On- Sickle Cell Disease Treatment Market
